Wuxi Biologics (Cayman)'s market cap is currently $99.80B. The company's EPS TTM is HK$0.683; its P/E ratio is 35.56; Wuxi Biologics (Cayman) is scheduled to report earnings on March 25, 2025, and the estimated EPS forecast is HK$0.47. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	¥ 17.03B	¥ 15.27B	¥ 10.29B	¥ 5.61B	¥ 3.98B
Gross Profit	¥ 6.83B	¥ 6.72B	¥ 4.83B	¥ 2.53B	¥ 1.66B
Operating Income	¥ 3.95B	¥ 6.16B	¥ 3.86B	¥ 1.76B	¥ 1.11B
EBITDA	¥ 5.50B	¥ 6.22B	¥ 4.51B	¥ 2.31B	¥ 1.37B
Net Income	¥ 3.40B	¥ 4.42B	¥ 3.39B	¥ 1.69B	¥ 1.01B
Balance Sheet
Cash & Short-Term Investments	¥ 11.24B	¥ 8.71B	¥ 11.13B	¥ 8.48B	¥ 6.75B
Total Assets	¥ 56.58B	¥ 49.56B	¥ 44.03B	¥ 28.96B	¥ 17.60B
Total Debt	¥ 4.56B	¥ 4.42B	¥ 4.30B	¥ 3.33B	¥ 2.19B
Net Debt	¥ -5.11B	¥ -1.97B	¥ -4.71B	¥ -3.76B	¥ -4.01B
Total Liabilities	¥ 12.56B	¥ 13.35B	¥ 11.33B	¥ 8.06B	¥ 4.71B
Stockholders' Equity	¥ 40.33B	¥ 35.05B	¥ 32.28B	¥ 20.56B	¥ 12.78B
Cash Flow
Free Cash Flow	¥ 437.20M	¥ -326.72M	¥ -3.09B	¥ -4.14B	¥ -2.03B
Operating Cash Flow	¥ 4.67B	¥ 5.54B	¥ 3.43B	¥ 1.88B	¥ 1.21B
Investing Cash Flow	¥ -3.23B	¥ -5.91B	¥ -9.60B	¥ -7.22B	¥ -4.49B
Financing Cash Flow	¥ 1.96B	¥ -2.59B	¥ 8.21B	¥ 6.57B	¥ 5.41B

Currency in CNY

Wuxi Biologics (Cayman) Earnings and Revenue History

Income Statement >

Wuxi Biologics (Cayman) Debt to Assets

Balance Sheet >

Wuxi Biologics (Cayman) Cash Flow

Cash Flow >

Wuxi Biologics (Cayman) Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing